JP2024526773A - B7‐h3抗体の医薬組成物及びその使用 - Google Patents
B7‐h3抗体の医薬組成物及びその使用 Download PDFInfo
- Publication number
- JP2024526773A JP2024526773A JP2024502056A JP2024502056A JP2024526773A JP 2024526773 A JP2024526773 A JP 2024526773A JP 2024502056 A JP2024502056 A JP 2024502056A JP 2024502056 A JP2024502056 A JP 2024502056A JP 2024526773 A JP2024526773 A JP 2024526773A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- enoblituzumab
- composition
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222750P | 2021-07-16 | 2021-07-16 | |
| US63/222,750 | 2021-07-16 | ||
| PCT/US2022/073462 WO2023288173A1 (en) | 2021-07-16 | 2022-07-06 | Pharmaceutical compositions of a b7-h3 antibody and use of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526773A true JP2024526773A (ja) | 2024-07-19 |
| JP2024526773A5 JP2024526773A5 (cg-RX-API-DMAC10.html) | 2025-07-10 |
Family
ID=84920541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024502056A Pending JP2024526773A (ja) | 2021-07-16 | 2022-07-06 | B7‐h3抗体の医薬組成物及びその使用 |
Country Status (11)
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013531679A (ja) * | 2010-07-02 | 2013-08-08 | メディミューン,エルエルシー | 抗体製剤 |
| US20140328750A1 (en) * | 2010-03-04 | 2014-11-06 | Macrogenics, Inc. | Antibodies Reactive with B7-H3 and Uses Thereof |
| WO2020200099A1 (zh) * | 2019-03-29 | 2020-10-08 | 江苏恒瑞医药股份有限公司 | 包含抗il-5抗体的药物组合物及其用途 |
| JP2021506922A (ja) * | 2017-12-22 | 2021-02-22 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Lag−3抗体医薬組成物およびその使用 |
| WO2021133653A1 (en) * | 2019-12-23 | 2021-07-01 | Macrogenics, Inc. | Therapy for the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230041197A1 (en) * | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| CN115103691B (zh) * | 2020-03-25 | 2025-01-24 | 苏州盛迪亚生物医药有限公司 | 一种含抗体药物偶联物的药物组合物及其用途 |
-
2022
- 2022-07-06 KR KR1020247004914A patent/KR20240038005A/ko active Pending
- 2022-07-06 AU AU2022310668A patent/AU2022310668A1/en not_active Abandoned
- 2022-07-06 IL IL310187A patent/IL310187A/en unknown
- 2022-07-06 US US18/577,945 patent/US20240336687A1/en active Pending
- 2022-07-06 EP EP22842996.5A patent/EP4370155A4/en not_active Withdrawn
- 2022-07-06 JP JP2024502056A patent/JP2024526773A/ja active Pending
- 2022-07-06 MX MX2024000690A patent/MX2024000690A/es unknown
- 2022-07-06 CA CA3224118A patent/CA3224118A1/en active Pending
- 2022-07-06 WO PCT/US2022/073462 patent/WO2023288173A1/en not_active Ceased
- 2022-07-06 CN CN202280050225.0A patent/CN117715657A/zh active Pending
- 2022-07-12 TW TW111126185A patent/TW202310874A/zh unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140328750A1 (en) * | 2010-03-04 | 2014-11-06 | Macrogenics, Inc. | Antibodies Reactive with B7-H3 and Uses Thereof |
| JP2013531679A (ja) * | 2010-07-02 | 2013-08-08 | メディミューン,エルエルシー | 抗体製剤 |
| JP2021506922A (ja) * | 2017-12-22 | 2021-02-22 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Lag−3抗体医薬組成物およびその使用 |
| WO2020200099A1 (zh) * | 2019-03-29 | 2020-10-08 | 江苏恒瑞医药股份有限公司 | 包含抗il-5抗体的药物组合物及其用途 |
| WO2021133653A1 (en) * | 2019-12-23 | 2021-07-01 | Macrogenics, Inc. | Therapy for the treatment of cancer |
Non-Patent Citations (1)
| Title |
|---|
| "A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men with Localized Intermediate- and High-", ジョンズホプキンス大学 プロトコル VER.4.0, JPN7026003331, 17 April 2019 (2019-04-17), pages 37 - 1, ISSN: 0005915578 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4370155A4 (en) | 2025-06-11 |
| WO2023288173A1 (en) | 2023-01-19 |
| AU2022310668A1 (en) | 2024-01-18 |
| CA3224118A1 (en) | 2023-01-19 |
| MX2024000690A (es) | 2024-02-07 |
| KR20240038005A (ko) | 2024-03-22 |
| US20240336687A1 (en) | 2024-10-10 |
| CN117715657A (zh) | 2024-03-15 |
| IL310187A (en) | 2024-03-01 |
| EP4370155A1 (en) | 2024-05-22 |
| TW202310874A (zh) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6113756B2 (ja) | 抗ang2抗体を含有する安定化製剤 | |
| US20150239970A1 (en) | Stable, Low Viscosity Antibody Formulation | |
| US20210252146A1 (en) | Stable antibody formulation | |
| TWI609696B (zh) | 包含抗-dll4抗體的穩定化調配物 | |
| SG11202108627SA (en) | Therapeutic antibody formulation | |
| US12364756B2 (en) | Pharmaceutical compositions of a PD-1 antibody and use of the same | |
| KR20240038005A (ko) | B7-h3 항체의 약학적 조성물 및 그것의 용도 | |
| KR20240100493A (ko) | 항-cd22 항체의 수성 제제 및 이의 용도 | |
| US11459399B2 (en) | Pharmaceutical compositions of a HER2/neu antibody and use of the same | |
| US20230053747A1 (en) | Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same | |
| CN116916952A (zh) | HER2/neu抗体的药物组合物及其用途 | |
| HK40112469A (en) | Pharmaceutical compositions of a pd-1 antibody and use of the same | |
| HK40102521A (en) | Pharmaceutical compositions of a her2/neu antibody and use of the same | |
| EA050933B1 (ru) | Фармацевтические композиции антитела к pd-1 и применение указанной композиции | |
| TWI771335B (zh) | 穩定藥學調配物 | |
| TW202128220A (zh) | 穩定液體組合物、其製備方法及含有其之調配物 | |
| WO2024190892A1 (ja) | 抗体製剤 | |
| KR20230026407A (ko) | 액티빈 a 항체 제형 및 이의 사용 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250702 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250702 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260716 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260724 |